title: [10-day triple therapy with esomeprazole 40 mg/12 h vs. quadruple concomitant non-bismuth therapy as first line treatment for Helicobacter pylori infection].
abstract: BACKGROUND
  Quadruple concomitant non-bismuth therapy has recently become the most widely prescribed first-line treatment for Helicobacter pylori infection in Spain. Whether optimized conventional triple therapy can achieve comparable efficacy rates remains to be seen.
  
  
  METHODS
  Retrospective study comparing the efficacy of triple and quadruple concomitant therapy, and sub-analysis following administration of both for 10 days with esomeprazole 40mg/12h.
  
  
  RESULTS
  A first-line therapy was administered to 657 patients from 1st January 2012 to 31st December 2014. Quadruple therapy (n=371) showed higher efficacy than triple therapy (n=248) for both intention-to-treat (85.9% vs. 65.7%; P<.001) and per protocol analysis (92.5% vs. 68.4%; P<.001). When both therapies included esomeprazole 40mg/12h administered for 10 days, quadruple concomitant therapy (n=108) also had higher efficacy than triple therapy (n=76) for intention-to-treat (90.7% vs. 73.6%; P=.003) and per protocol analysis (92.5% vs.74.6%; P=.002).
  
  
  CONCLUSIONS
  Quadruple concomitant therapy with high dose proton pump inhibitor (PPI) for 10 days achieves a significantly higher eradication outcome than optimized triple therapy, with rates of over 90% when the PPI prescribed is esomeprazole 40mg/12h.
authors.affiliation: Aparato Digestivo, Hospital Reina Sofía, Tudela, Navarra, España. Electronic address: campilloarregui@gmail.com.
authors.forename: Ana
authors.initials: A
authors.lastname: Campillo
authors.affiliation: Aparato Digestivo, Hospital Reina Sofía, Tudela, Navarra, España.
authors.forename: Edurne
authors.initials: E
authors.lastname: Amorena
authors.affiliation: Aparato Digestivo, Hospital Reina Sofía, Tudela, Navarra, España.
authors.forename: Miriam
authors.initials: M
authors.lastname: Ostiz
authors.affiliation: Aparato Digestivo, Hospital Reina Sofía, Tudela, Navarra, España.
authors.forename: Marcos
authors.initials: M
authors.lastname: Kutz
authors.affiliation: Aparato Digestivo, Hospital Reina Sofía, Tudela, Navarra, España.
authors.forename: Matilde
authors.initials: M
authors.lastname: LaIglesia
mesh_terms: D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000008:administration & dosage / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D017291:Clarithromycin / Q000008:administration & dosage / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D004415:Dyspepsia / Q000188:drug therapy / Q000382:microbiology; D064098:Esomeprazole / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005756:Gastritis / Q000188:drug therapy* / Q000382:microbiology; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D054328:Proton Pump Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D012189:Retrospective Studies; D013030:Spain; D013276:Stomach Ulcer / Q000188:drug therapy / Q000382:microbiology
chemical_list: D000900:Anti-Bacterial Agents; D054328:Proton Pump Inhibitors; D008795:Metronidazole; D000658:Amoxicillin; D017291:Clarithromycin; D064098:Esomeprazole
keywords: Helicobacter pylori; Quadruple concomitant therapy; Terapia cuádruple concomitante; Triple terapia; Triple therapy